- Home
- MDIA vs VNRX Comparison
MDIA vs VNRX Comparison
Compare MDIA & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDIA
- VNRX
- Stock Information
- Founded
- MDIA 2019
- VNRX N/A
- Country
- MDIA United States
- VNRX United States
- Employees
- MDIA N/A
- VNRX N/A
- Industry
- MDIA Broadcasting
- VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- MDIA Consumer Discretionary
- VNRX Health Care
- Exchange
- MDIA Nasdaq
- VNRX Nasdaq
- Market Cap
- MDIA 55.6M
- VNRX 58.6M
- IPO Year
- MDIA N/A
- VNRX N/A
- Fundamental
- Price
- MDIA $1.09
- VNRX $0.59
- Analyst Decision
- MDIA
- VNRX Strong Buy
- Analyst Count
- MDIA 0
- VNRX 4
- Target Price
- MDIA N/A
- VNRX $4.17
- AVG Volume (30 Days)
- MDIA 16.4K
- VNRX 106.2K
- Earning Date
- MDIA 03-31-2025
- VNRX 03-24-2025
- Dividend Yield
- MDIA N/A
- VNRX N/A
- EPS Growth
- MDIA N/A
- VNRX N/A
- EPS
- MDIA N/A
- VNRX N/A
- Revenue
- MDIA $69,296,000.00
- VNRX $1,285,827.00
- Revenue This Year
- MDIA N/A
- VNRX $71,446.31
- Revenue Next Year
- MDIA N/A
- VNRX N/A
- P/E Ratio
- MDIA N/A
- VNRX N/A
- Revenue Growth
- MDIA 94.96
- VNRX 97.50
- 52 Week Low
- MDIA $0.40
- VNRX $0.43
- 52 Week High
- MDIA $6.86
- VNRX $1.09
- Technical
- Relative Strength Index (RSI)
- MDIA 44.65
- VNRX 48.15
- Support Level
- MDIA $1.00
- VNRX $0.55
- Resistance Level
- MDIA $1.23
- VNRX $0.65
- Average True Range (ATR)
- MDIA 0.08
- VNRX 0.04
- MACD
- MDIA -0.00
- VNRX 0.00
- Stochastic Oscillator
- MDIA 38.46
- VNRX 40.00
About MDIA Mediaco Holding Inc.
MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales and events including sponsorships and ticket sales, licensing, and syndication.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.